US 12,405,488 B2
Ophthalmic devices
Alok Kumar Awasthi, Pittsford, NY (US); Kristen Rae Hovinga, Honeoye Falls, NY (US); Emily Abrams Gabriel, Pittsford, NY (US); Kevin Jacob DeRyke, Webster, NY (US); Jade J. Russell, Perry, NY (US); and Alana Ingham, Hilton, NY (US)
Assigned to BAUSCH + LOMB IRELAND LIMITED, Dublin (IE)
Filed by Bausch + Lomb Ireland Limited, Dublin (IE)
Filed on Jun. 9, 2022, as Appl. No. 17/836,258.
Claims priority of provisional application 63/239,246, filed on Aug. 31, 2021.
Prior Publication US 2023/0097637 A1, Mar. 30, 2023
Int. Cl. G02C 7/10 (2006.01); A61L 12/14 (2006.01); C07C 301/02 (2006.01); C07D 205/06 (2006.01); C07D 279/08 (2006.01); C07D 403/10 (2006.01); C07D 403/14 (2006.01); C07D 409/06 (2006.01); G02C 7/04 (2006.01)
CPC G02C 7/107 (2013.01) [A61L 12/147 (2013.01); C07C 301/02 (2013.01); C07D 205/06 (2013.01); C07D 279/08 (2013.01); C07D 403/10 (2013.01); C07D 403/14 (2013.01); C07D 409/06 (2013.01); G02C 7/049 (2013.01); G02C 2202/24 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A method for preparing an ophthalmic device containing one or more red-light blocking compounds, the method comprising:
(a) soaking an ophthalmic device in one or more first solvent solutions to swell the ophthalmic device;
(b) soaking the swelled ophthalmic device in one or more second solvent solutions comprising one or more red-light blocking compounds blocking greater than about 5% to about 25% of red-light transmission through the ophthalmic device at a wavelength of from about 550 nanometers (nm) to about 800 nm to de-swell the swelled ophthalmic device and entrap the one or more red-light blocking compounds in the de-swelled ophthalmic device; and
(c) sterilizing the de-swelled ophthalmic device;
wherein the one or more first solvent solutions comprise a blend of a low molecular weight alcohol solvent and water, and the ophthalmic device is soaked in the one or more first solvent solutions for a time period ranging from about 5 minutes to about 120 minutes.